pretickt

Is BDX a good stock to buy?

Becton, Dickinson and Company · end-of-day data as of Nov 13, 2026

Becton Dickinson
BDX · $59.39B
$218.03+1.1%
Nov 13, 2026 · close
$180$200$220SepOctNov9:3016:003 months +21.3%Nov 13 · close
▲ 5
  • FCF yield+4.7%
  • Trendbullish
  • MAs4 of 4
  • MACD1.16
  • Sector▲ +15.9%
Neutral
  • Earnings in87d
  • P/E52.7x
  • Support-13.2%
  • Off 52w high-0.8%
  • Volume1.0x
  • Bollingerupper half
  • News0.00
  • ConsensusHold · 17
  • 52w range$140–$220
  • ATR+2.1%
  • Off ATH-3.5%
▼ 5
  • PT$189.51 -13.1%
  • P/E vs own+37.2%
  • P/E vs sector+63.5%
  • Insiders-$689K
  • RSI76

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Becton Dickinson a good stock to buy?

Becton Dickinson is strong on 2 of the 5 questions about the business; weak on advantage. The price is high: 52.7 times its earnings, above its 3-year median of 36.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage easy to copy
  3. Economics profitable
  4. Execution delivers
  5. Fragility sturdy
  6. Price expensive
DemandDo people want more of what it sells?steady

BDX sales growth revenue growth

+1%a year, for the last 3 years

Becton Dickinson's sales grew 1% a year for 3 years, to $20.22B in fiscal 2026.

BDX analysts' forecast revenue estimates

-3%the sales they expect next fiscal year, on the last

Analysts expect Becton Dickinson's sales to fall 3% to $19.69B in fiscal 2027 (10 analysts).

BDX competitors

pretickt analysis-7%its sales in 12 months, on a year before

Becton Dickinson's sales fell 7% in the 12 months to Sep 30, 2026; Intuitive Surgical's grew 20%, West Pharmaceutical Services' grew 13%, ResMed's grew 9% and Solventum's fell 3%.

BDX sales by business revenue by segment

52%of its sales from Medical

Medical brought Becton Dickinson 52% of its sales in fiscal 2025; Interventional 24%.

Advantage moatIs it hard to copy?easy to copy

BDX return on capital ROIC

pretickt analysis4%earned before tax on the money invested in it

Becton Dickinson earned 4% before tax on the capital invested in it in the 12 months to Sep 30, 2026; ResMed 34%, West Pharmaceutical Services 28%, Intuitive Surgical 25% and Solventum 21%.

BDX margin on each sale gross margin

47%left after making the product

Becton Dickinson kept 47% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 58%.

EconomicsDoes it make good money?profitable

BDX margin after costs profit margin

12%of sales left after running the business

Becton Dickinson's operating margin was 12% in the 12 months to Sep 30, 2026, against 11% in fiscal 2023.

BDX cash generated free cash flow

$2.81Bcash left after investing, last 12 months

Becton Dickinson generated $2.81B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

BDX profit per share

-29%in its last fiscal year

Becton Dickinson's earnings per share fell 29% in fiscal 2026, to $4.14.

ExecutionDoes it deliver what it promises?delivers

BDX earnings vs estimates

8 of 8quarters above the analysts' estimate

Becton Dickinson beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 5, 2026.

BDX insider selling

-$3.38Msold, net, by its executives in 12 months

Becton Dickinson's executives and directors sold a net $3.38M of shares in the 12 months to Nov 13, 2026; none bought.

BDX number of employees

-3%fewer people in a year

Becton Dickinson had 72,000 employees at the end of fiscal 2025, 3% fewer than a year before.

BDX CEO pay

$17.13Mfor fiscal 2025, 78% of it in stock and options

Becton Dickinson paid its CEO $17.13M for fiscal 2025, 78% of it in stock and options.

Fragility risksCould something break it?sturdy

BDX financial health Altman Z-score

1.9Altman Z-score, safe above 3

Becton Dickinson's Altman Z-score is 1.9 (Nov 13, 2026), between 1.8 and 3, the grey zone.

BDX quality checks Piotroski score

8 of 9checks passed

Becton Dickinson passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets.

BDX biggest customers

under 10%of sales from any one customer

No customer made 10% of Becton Dickinson's sales in fiscal 2025.

Price valuationIs the price reasonable?expensive

BDX price vs profit P/E ratio

52.7×a year's earnings

Becton Dickinson's P/E ratio is 52.7 (Nov 13, 2026), above its 3-year median of 36.1.

BDX price vs competitors

pretickt analysis52.7×a year's earnings, against its competitors

Investors pay 52.7 times Becton Dickinson's earnings (Nov 13, 2026), more than for West Pharmaceutical Services (46.7) and ResMed (21.9), less than for Solventum (99.0) and Intuitive Surgical (53.3).

BDX analysts' target price target

-13%to their average target

Analysts' average price target for Becton Dickinson is $190, 13% below the Nov 13, 2026 close of $218.03.

BDX analyst ratings, 90 days

pretickt analysis
  • Wells Fargoupgrade
1 up, 0 downratings raised and cut

In the 90 days to Nov 13, 2026, Wells Fargo upgraded Becton Dickinson.

BDX growth priced in fair value

pretickt analysis+8%a year, for ten years, to be worth the price

At $218.03 a share, Becton Dickinson's free cash flow must grow about 8% a year for ten years to be worth the price (Nov 13, 2026).

What is Becton Dickinson's P/E ratio?

Becton Dickinson's P/E ratio is 52.7 (Nov 13, 2026), above its 3-year median of 36.1. Investors pay 52.7 times Becton Dickinson's earnings (Nov 13, 2026), more than for West Pharmaceutical Services (46.7) and ResMed (21.9), less than for Solventum (99.0) and Intuitive Surgical (53.3).

Who are Becton Dickinson's biggest competitors?

pretickt compares Becton Dickinson with ResMed, West Pharmaceutical Services, Intuitive Surgical and Solventum. Becton Dickinson's sales fell 7% in the 12 months to Sep 30, 2026; Intuitive Surgical's grew 20%, West Pharmaceutical Services' grew 13%, ResMed's grew 9% and Solventum's fell 3%.

Is Becton Dickinson profitable?

Becton Dickinson's operating margin was 12% in the 12 months to Sep 30, 2026, against 11% in fiscal 2023. Becton Dickinson generated $2.81B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

Are insiders selling Becton Dickinson stock?

Becton Dickinson's executives and directors sold a net $3.38M of shares in the 12 months to Nov 13, 2026; none bought.

How does Becton Dickinson make money?

Medical brought Becton Dickinson 52% of its sales in fiscal 2025; Interventional 24%.

How many employees does Becton Dickinson have?

Becton Dickinson had 72,000 employees at the end of fiscal 2025, 3% fewer than a year before.

Who are Becton Dickinson's biggest customers?

No customer made 10% of Becton Dickinson's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.